These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 21314492)

  • 1. A neoteric annotation on the advances in combination therapy for Parkinson's disease: nanocarrier-based combination approach and future anticipation. Part II: nanocarrier design and development in focus.
    Unnithan D; Sartaj A; Iqubal MK; Ali J; Baboota S
    Expert Opin Drug Deliv; 2024 Mar; 21(3):437-456. PubMed ID: 38507231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug development in Parkinson's disease: from emerging molecules to innovative drug delivery systems.
    Garbayo E; Ansorena E; Blanco-Prieto MJ
    Maturitas; 2013 Nov; 76(3):272-8. PubMed ID: 23827471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Continuous drug delivery in Parkinson's disease.
    Senek M; Nyholm D
    CNS Drugs; 2014 Jan; 28(1):19-27. PubMed ID: 24323838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanistic Insights, Treatment Paradigms, and Clinical Progress in Neurological Disorders: Current and Future Prospects.
    Alkahtani S; Al-Johani NS; Alarifi S
    Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674852
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Shen LM; Li MC; Wei WJ; Guan X; Liu J
    ACS Omega; 2021 Nov; 6(47):32133-32141. PubMed ID: 34870034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intranasal Delivery of Nanoformulations: A Potential Way of Treatment for Neurological Disorders.
    Islam SU; Shehzad A; Ahmed MB; Lee YS
    Molecules; 2020 Apr; 25(8):. PubMed ID: 32326318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized controlled efficacy study of the Medido medication dispenser in Parkinson's disease.
    Hannink K; Ter Brake L; Oonk NGM; Wertenbroek AA; Piek M; Vree-Egberts L; Faber MJ; van der Palen J; Dorresteijn LD
    BMC Geriatr; 2019 Oct; 19(1):273. PubMed ID: 31619184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fabrication, Optimization, and Evaluation of Rotigotine-Loaded Chitosan Nanoparticles for Nose-To-Brain Delivery.
    Tzeyung AS; Md S; Bhattamisra SK; Madheswaran T; Alhakamy NA; Aldawsari HM; Radhakrishnan AK
    Pharmaceutics; 2019 Jan; 11(1):. PubMed ID: 30634665
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic nanoplatforms and delivery strategies for neurological disorders.
    Kang YJ; Cutler EG; Cho H
    Nano Converg; 2018 Nov; 5(1):35. PubMed ID: 30499047
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug Delivery Systems for Imaging and Therapy of Parkinson's Disease.
    Gunay MS; Ozer AY; Chalon S
    Curr Neuropharmacol; 2016; 14(4):376-91. PubMed ID: 26714584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Compliance with pharmacotherapy and direct healthcare costs in patients with Parkinson's disease: a retrospective claims database analysis.
    Richy FF; Pietri G; Moran KA; Senior E; Makaroff LE
    Appl Health Econ Health Policy; 2013 Aug; 11(4):395-406. PubMed ID: 23649891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liposomes for Targeted Delivery of Active Agents against Neurodegenerative Diseases (Alzheimer's Disease and Parkinson's Disease).
    Spuch C; Navarro C
    J Drug Deliv; 2011; 2011():469679. PubMed ID: 22203906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Levodopa delivery systems: advancements in delivery of the gold standard.
    Ngwuluka N; Pillay V; Du Toit LC; Ndesendo V; Choonara Y; Modi G; Naidoo D
    Expert Opin Drug Deliv; 2010 Feb; 7(2):203-24. PubMed ID: 20095943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatments for Parkinson disease--past achievements and current clinical needs.
    Poewe W
    Neurology; 2009 Feb; 72(7 Suppl):S65-73. PubMed ID: 19221317
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Levodopa in Parkinson's disease: from the past to the future.
    Pezzoli G; Zini M
    Expert Opin Pharmacother; 2010 Mar; 11(4):627-35. PubMed ID: 20163273
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levodopa/dopamine replacement strategies in Parkinson's disease--future directions.
    Olanow CW
    Mov Disord; 2008; 23 Suppl 3():S613-22. PubMed ID: 18781663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Levodopa in the treatment of Parkinson's disease: current controversies.
    Olanow CW; Agid Y; Mizuno Y; Albanese A; Bonuccelli U; Damier P; De Yebenes J; Gershanik O; Guttman M; Grandas F; Hallett M; Hornykiewicz O; Jenner P; Katzenschlager R; Langston WJ; LeWitt P; Melamed E; Mena MA; Michel PP; Mytilineou C; Obeso JA; Poewe W; Quinn N; Raisman-Vozari R; Rajput AH; Rascol O; Sampaio C; Stocchi F
    Mov Disord; 2004 Sep; 19(9):997-1005. PubMed ID: 15372588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New non-oral drug delivery systems for Parkinson's disease treatment.
    Md S; Haque S; Sahni JK; Baboota S; Ali J
    Expert Opin Drug Deliv; 2011 Mar; 8(3):359-74. PubMed ID: 21314492
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.